RxDoctor Payments Data

Michael McEvoy, MD

Family Medicine · Eldersburg, MDNPI 1669558219

Payments from drug & device makers

$9,728in general payments, 2019–2025

Across 583 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$942
  • Pfizer$937
  • Amgen$828
  • Lilly USA, LLC$677
  • Amarin Pharma, Inc.$553
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$9,716100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,728 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$791,018
Medicare patients
1,350
Services billed
11,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$125,858
RybelsusSemaglutide40$104,540
JardianceEmpagliflozin77$102,817
TrulicityDulaglutide61$101,275
EliquisApixaban53$62,748
JanuviaSitagliptin Phosphate23$33,116
MounjaroTirzepatide31$31,687
XareltoRivaroxaban29$27,611
FarxigaDapagliflozin Propanediol18$22,481
MyrbetriqMirabegron22$13,883
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$13,578
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$13,358
Trijardy XrEmpaglifloz/Linaglip/Metformin11$12,500
GemtesaVibegron11$7,884
Ezetimibe-SimvastatinEzetimibe/Simvastatin58$6,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$942$230,398125 claims
Lilly USA, LLCTrulicity, Mounjaro$677$132,96292 claims
Boehringer IngelheimJardiance, Trijardy Xr$110$115,31788 claims
PfizerEliquis$937$62,74853 claims
MerckJanuvia$92$33,11623 claims
AstraZenecaFarxiga, Symbicort$544$28,84330 claims
Johnson & JohnsonXarelto$165$27,61129 claims
Astellas Pharma US IncMyrbetriq$325$13,88322 claims
GSKAnoro Ellipta$535$13,57827 claims
Sumitomo Pharma America, Inc.Gemtesa$57$7,88411 claims
Esperion Therapeutics, Inc.Nexlizet$293$5,23413 claims
AbbVieSynthroid$1,420$2,43563 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Eldersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →